Press releases

New US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding NGS

BIOCARTIS MEETS 2020 KEY OBJECTIVES

Disclosure of outstanding voting securities

Biocartis Announces the Conversion of EUR 15 million of its EUR 150 million 4% Convertible Bonds due 2024

Disclosure of a transparency notification

Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods

Biocartis Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

BIOCARTIS Q3 2020 BUSINESS UPDATE

Biocartis Announces CE-marking of its Fully Automated Idylla™ SARS-CoV-2 Test

Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness